Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free SCPS Stock Alerts

Scopus BioPharma (SCPS) Competitors

Scopus BioPharma logo
$0.0004 0.00 (0.00%)
As of 09/2/2026
Compare

SCPS vs. VINC, CARM, SMFL, NAVB, and GNCA

Should you buy Scopus BioPharma stock or one of its competitors? Scopus BioPharma's main competitors and comparable companies include Vincerx Pharma (VINC), Carisma Therapeutics (CARM), Smart for Life (SMFL), Navidea Biopharmaceuticals (NAVB), and Genocea Biosciences (GNCA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Scopus BioPharma compare to Vincerx Pharma?

Vincerx Pharma (NASDAQ:VINC) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Vincerx Pharma has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.19, suggesting that its stock price is 119% less volatile than the broader market.

44.0% of Vincerx Pharma shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Vincerx Pharma Neutral
Scopus BioPharma Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
Scopus BioPharma N/A N/A N/A

Summary

Vincerx Pharma and Scopus BioPharma tied by winning 3 of the 6 factors compared between the two stocks.

How does Scopus BioPharma compare to Carisma Therapeutics?

Scopus BioPharma (NASDAQ:SCPS) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

Scopus BioPharma has higher earnings, but lower revenue than Carisma Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00

Scopus BioPharma has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Carisma Therapeutics -254.28%N/A -192.17%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scopus BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Carisma Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Scopus BioPharma has a beta of -0.19, indicating that its stock price is 119% less volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of -9.01, indicating that its stock price is 1,001% less volatile than the broader market.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Carisma Therapeutics Neutral

44.3% of Carisma Therapeutics shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Scopus BioPharma and Carisma Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Scopus BioPharma compare to Smart for Life?

Smart for Life (NASDAQ:SMFL) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Scopus BioPharma Neutral

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Scopus BioPharma N/A N/A N/A

Scopus BioPharma has lower revenue, but higher earnings than Smart for Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

28.4% of Smart for Life shares are held by institutional investors. 31.7% of Smart for Life shares are held by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Smart for Life has a beta of 15.1, suggesting that its stock price is 1,410% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.19, suggesting that its stock price is 119% less volatile than the broader market.

Summary

Smart for Life beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

How does Scopus BioPharma compare to Navidea Biopharmaceuticals?

Scopus BioPharma (NASDAQ:SCPS) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Scopus BioPharma has a beta of -0.19, suggesting that its share price is 119% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market.

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Scopus BioPharma has higher earnings, but lower revenue than Navidea Biopharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Navidea Biopharmaceuticals Neutral

Summary

Navidea Biopharmaceuticals beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

How does Scopus BioPharma compare to Genocea Biosciences?

Scopus BioPharma (NASDAQ:SCPS) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Scopus BioPharma's return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Genocea Biosciences N/A -182.88%-62.76%

Scopus BioPharma has higher earnings, but lower revenue than Genocea Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

Scopus BioPharma has a beta of -0.19, meaning that its stock price is 119% less volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Genocea Biosciences Neutral

0.6% of Genocea Biosciences shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Scopus BioPharma beats Genocea Biosciences on 4 of the 7 factors compared between the two stocks.

Get Scopus BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCPS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCPS vs. The Competition

Export
MetricScopus BioPharmaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$17K$12.25B$7.26B$12.73B
Dividend YieldN/A2.59%2.53%8.86%
P/E RatioN/A787.27273.2925.25
Price / SalesN/A754.88623.6797.64
Price / CashN/A94.8077.8252.26
Price / BookN/A12.3312.926.14
Net Income-$11.61M$2.82B$3.47B$349.01M
7 Day PerformanceN/A2.60%0.60%-0.27%
1 Month PerformanceN/A6.96%5.72%0.68%
1 Year PerformanceN/A9.45%25.33%14.84%

Scopus BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCPS
Scopus BioPharma
N/A$0.00
flat		N/AN/A$17KN/AN/A9
VINC
Vincerx Pharma
N/A$0.01
flat		N/AN/A$66KN/AN/A60
CARM
Carisma Therapeutics
0.3354 of 5 stars		$0.00
+8.3%		N/A-99.8%$50K$10.77M0.0020
SMFL
Smart for Life
N/A$0.00
flat		N/A-92.6%$14K$11.11MN/A110
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SCPS) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel